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Poster Session-I 49At the time of transplant, 21 pts (57%) were in complete remission
(CR) (CR1 5 20%) and 16 had relapsed/refractory disease. Grafts
consisted of double (29 pts) or single (8 pts) CB units. Donor recip-
ient HLA matching (n5 66 units) was 3/6 (n5 1, 1.5%), 4/6 (n5 47,
71.2%) and 5/6 (n 5 18, 27.3%) alleles. Median TNC infused was
1.8  107/kg (range 1–5.8). 19 pts received ex-vivo expanded units.
The conditioning regimen consisted of melphalan 140 mg/m2 on
day -8, thiotepa 10 mg/m2 on day -7, fludarabine 160 mg/m2 over
4 days on days -6 to -3, and rabbit ATG 1.25 mg/kg on day -4 and
1.75 mg/kg on day -3 (FMT). Patients with CD 201 lymphoid ma-
lignancies also received rituximab 375mg/m2 on day -9 (n5 8, 22%).
GVHD prophylaxis was tacrolimus and mini-methotrexate in 23
(62%) and tacrolimus and mycophenolate in 14 pts (38%).
Results: 34/36 evaluable pts (95%) engrafted neutrophils and had
hematopoietic recovery with 100% cord blood-derived cells. At day
30, of the 29 pts who received a double CBT, 75% had chimerism
derived entirely from one donor while 25% had mixed donors chi-
merism. Neutrophil recovery occurred after a median of 21 days
(range 6–45) and platelet recovery after a median of 37 days (range
26–134, N5 24; 67%). 32/37 pts (87%) were in CR after transplant
with 16 surviving after a median follow-up of 12.1 months. Thirteen
pts (36%) developed gr II-IV aGVHD (gr III-IV aGVHD in 5 pts,
14%), and 13 of 32 pts had cGVHD (40%), with the majority expe-
riencing extensive GVHD. 11 pts (29.7%) relapsed after a median of
7 months post transplant and 12 died of non-relapse causes. Day-100
treatment-related mortality (TRM) in this heavily pre-treated
population was 10%. Overall, causes of death included disease
relapse (n 5 9), infections (n 5 6), organ failure (n 5 3), pulmonary
hemorrhage (n 5 1) and GVHD (n 5 2).
Conclusions: The FMT regimen is associated with a high rate of
engraftment and low TRM in adult pts undergoing CBT which
supports its further evaluation in CBT.126
ALTENATIVE DONOR PERIPHERAL STEM CELL TRANSPLANT (PSCT)
WITH CD31 DEPLETION AND CD31 ADDBACK FOR PEDIATRIC
PATIENTS WITH LEUKEMIAS
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Most patients (pts) with leukemias who may benefit from alloge-
neic HSCT lack matched related donors (MRD), and due to diverse
ethnic backgrounds, matched unrelated donors may be unavailable
in a timely fashion. High doses of mobilized PSCs may decrease
time to engraftment and relapse risk, but most studies report an in-
creased risk of extensive chronic GVHD. Partial T depletion allows
the use of alternative donors, while potentially retaining graft vs leu-
kemia(GVL) effect and ensuring engraftment. We began a pilot
study in 2005 for pts with leukemias or myelodysplastic syndromes
who lacked MRD using CD31 depleted PSCs with a defined dose
of CD31 at the time of infusion. Conditioning included thiotepa
5mg/kg  2 d, cyclophosphamide 60 mg/kg  2 d, TBI 1200 cGy.
Clinimacs device was used for CD31 depletion, and an aliquot of in-
tact PSCs was cryopreserved for potential donor lymphocyte infu-
sion (DLI). GVHD prophylaxis included cyclosporine followed by
oral tacrolimus. Initial CD31 dose was 0.2 105/kg, but this was es-
calated to a maximum of 5 105/kg depending upon HLA disparity.
This report includes the first 28 pts with at least 6 months follow up
(median, 18 months, 9–41). Patients included 17 males, median age
12 years (0.8–20). Diagnoses included ALL -13, AML - 6, MDS/
MPD-5, JMML-1,CML-3. Donors were unrelated for 25, and re-
lated (father, brother, aunt) for 3. Donors were high resolution 10/
10 matched for 8 pts (30%); 7 had single antigen or allele mis-
matches, 9 had 2 mismatches and 4 had 3. Pts received a median of
5  106/kg CD341 (3–10) and a median of 1.8  105/kg CD31
(0.5–8). Engraftment occurred in all pts, with ANC.500 at a median
of 16 days (10–26) and platelets.20k at a median of 13 days (8–28).
Acute GVHD occurred in 17 pts, and was overall grade I-II in 14,
III-IV in 3 (10.7%) Chronic GVHD developed in 7/24 evaluable
pts (29%) and was extensive in 4 (17%). TRM occurred in 5 pts be-
fore d1175 from ARDS (1), liver failure/VOD (2), invasive fungus
(1) and GVHD/MSOF (1). Relapses occurred in 5 pts (ALL-3,
AML/MPD-2) at 3- 12 months and 2 CML pts developed mixed chi-
merism. Three pts with AML, MPD, and CML who received DLI
have full donor chimerism 24–41 months post SCT. EFS is 57%and OS 68 % including pts in remission following DLI. CD31 de-
pletion with a defined dose of CD31 provides durable engraftment,
maintains GVL, and allows use of mismatched donors. Additional
study is needed to define optimal dose and type of T cell addback.127
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We studied the clinical outcomes of 113 adults with hematologic
malignancies who received unrelated cord blood transplantation
(CBT) after myeloablative preparative regimens including 12 Gy to-
tal body irradiation. All patients received same graft-versus-host dis-
ease (GVHD) prophylaxis consisted of cyclosporine (CsA; 3mg/kg
intravenous infusion over 10 hours) and short-term methotrexate
(MTX; 15mg/m2 on day1 and 10mg/m2 on days 3 and 6). CsA was
reduced due to impaired renal function or was tapered beginning
between weeks 6 and 9 in the absence of GVHD in our protocol. Me-
dian number of nucleated cells in infused cord blood was 2.37 107/
kg (range 1.73 to 5.29 107/kg). Cord blood grafts were mismatched
0 to 4 of 6 HLA-A, -B (antigen level), and -DRB1 (allele level) to the
recipient. Engraftment was achieved in 105 of 113 patients and those
were subjected to be analyzed for acute GVHD. Of the 105 evaluable
patients, the incidence of grade II to IV and III to IV acute GVHD
was 62.9 % and 8.6 %, respectively. Ninety five patients survived
more than 100 days and extensive type chronic GVHD occurred in
24.2 %. Of the 113 patients, 72 were alive and disease-free between
333 and 3658 days after CBT (median 1558 days). In 105 evaluable
patients, median day of tapering and 50% reduction of CsA was 28
(range 0 to 110) days and 39 days (range 4 to 142) after transplanta-
tion, respectively. The average of trough CsA level after 1 week, 2
weeks, 3 weeks, and 4 weeks was 177, 149, 160, and 166 ng/ml,
respectively. In 54 of 105 patients, trough CsA levels were more
than 160 ng/ml on day 28 and none had grade III to IV acute
GVHD. The incidence of extensive type chronic GVHD was 13.7
% in 51 evaluable patients whose trough CsA levels were more
than 160ng/ml on day 28. These results suggested that cyclosporine
and short-term MTX effectively prevented the occurrence of severe
GVHD after myeloablative CBT and blood CsA levels should be
monitored carefully during early phase after transplantation.128
ANTIBODIES ARE DETECTED AGAINST MISMATCHED HLA CLASS II AL-
LELES AND NOT CLASS I FOLLOWING ALLOGENEIC HEMATOPOIETIC
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This pilot study sought to determine whether alloantibody to
HLA is made in patients with acute GVHD. Day 100 serum samples
of 40 recipient-donor pairs of (theoretically) single antigen/allele
HLA-mismatched (MM) unrelated donor transplants performed be-
tween July 1990 and June 1999 were obtained in collaboration with
the CIBMTR and NMDP. All recipients had developed acute
GVHD. We measured HLA class I and II antibody (Ab) levels to
the MM alleles in both the graft-versus-host (GVH) and host-
versus-graft (HVG) directions. Allele level typing for eight loci (A,
B, C, DRB1, DQB1, DQA1, DPB1, DPA1) was compared between
donor and recipient to identify all mismatches. GVH disparity meant
the allele expressed in the recipient was absent in the donor. HVG
disparity meant the allele expressed in the donor was absent in the re-
cipient. In general, we observed more than a single allele MM in
these pairs. Sera were screened for IgG antibody to the MM HLA
alleles using single antigen beads covering 96 different class I
50 Poster Session-I(A,B,C) and 56 different class II (DR,DQ,DP) alleles on a Luminex
platform (One Lambda, Canoga Park, CA) to determine antibody
production in both the GVH and HVG directions. Since the thresh-
old Ab response to HLA MM in marrow transplantation is unknown,
we applied the established scale from solid organ transplantation
where $1000 is positive, 500–999 is possible, and\500 is negative.
The limitation of the analysis is that the beads contain every antigen
but not every allele. In the 40 pairs, no anti-A, B, or C allele-specific
antibodies were detected at day 100 in either direction. Results for
class II antibody are shown in the table below. There is evidence
for class II allele-specific antibody production to the MM allele in
both the GVH and HVG directions with the highest frequency Ab
seen against DPA1. In conclusion, day 100 Ab to class II rather
than class I allele MM are observed in this pilot study. This may re-
flect greater immunogenicity of class II as compared to class I, a long-
standing observation in transplantation. Current studies to
determine if these are de novo or preformed Ab are being performed
using pretransplant sera from these same pairs. Future studies will
look at Ab association with GVHD and disease relapse with attention
to class II on B cells as a meaningful GVL target.
Class II Antibody Analysis
DRB1 DQB1 DQA1 DPB1 DPA1# of GVH
disparate alleles8 13 8 46 14Allele Ab test
available3 7 5 13 11Frequency of
Ab$ 10000 0 0 2/13 (15%) 2/11 (18%)Frequency of
Ab$5002/3 (67%) 2/7 (29%) 0 4/13 (31%) 6/11 (55%)# of HVG
disparate alleles8 13 9 44 13Allele Ab test
available1 2 6 17 10Frequency of
Ab$10000 0 0 0 2/10 (20%)Frequency of
Ab$5001/1 (100%) 0 0 5/17 (29%) 7/10 (70%)GVH5graft-versus-host; HVG5host-versus-graft.129
IS THERE REALLY A DIFFERENCE IN OUTCOME AND INCIDENCE OF
ACUTE/CHRONIC GVHD IN PATIENTS UNDERGOING UNMANIPULATED
MUD-PBSCT VS MUD-BMT? SINGLE LARGE PEDIATRIC CENTER EXPERI-
ENCE
Kalwak, K., Porwolik, J., Gorczynska, E., Owoc-Lempach, J.,
Ussowicz, M., Musial, J., Dyla, A., Pazdzior, D., Wojcik, D.,
Skarzynska, M., Chybicka, A. Wroclaw Medical University, Wroclaw,
Poland
There is an unresolved question whether unmanipulated matched
unrelated donor (MUD) PBSCT leads to a worse overall outcome
and higher incidence of severe GvHD in comparison with well estab-
lished MUD-BMT. It is well known that PBSC grafts contain ca 1
log more mature T cells, which may result in higher rate of severe
and often fatal acute/chronic GvHD after MUD-PBSCT. The aim
of our study was to compare the results of MUD-PBSCT vs
MUD-BMT in a large mostly pediatric patient population. We an-
alyzed the records of 177 consecutive pts (with hematologic malig-
nancies, n 5 148 and non-malignant disorders, n 5 29), who
underwent MUD-BMT (42 pts) or MUD-PBSCT (135 pts) between
1999 and February 2008 in our department. Probability of overall
survival for all pts after MUD-PBSCT was 0.54 and after
MUD-BMT was 0.46 (p 5 NS). Median follow-up of surviving 97
pts (55%) was 3 years. Furthermore, there was no difference between
the probability of incidence of both acute GvHD grade III-IV be-
tween the recipients of MUD-PBSCT (0.2) or MUD-BMT (0.25)
and extensive chronic GvHD (0.21 for MUD-PBSCT recipients
and 0.18 for MUD-BMT recipients). With regard to ‘‘high resolu-tion’’ HLA match, 84 donor-recipient pairs were fully matched,
whereas 64 were mismatched at one, 24 at two and 5 at three loci.
Probability of survival, acute GvHD grades III-IV and extensive
cGvHD were for respective groups as follows: 0.53, 0.18, 0.17 for
10 of 10 allele matched group, 0.47, 0.21, 0.18 for 9 of 10 allele
matched group and surprisingly 0.58, 0.27 and 0.27 for 8 of 10 allele
matched group. In the latter group, however, if two HLA antigens
were mismatched the probability of survival decreased to 0.38, prob-
ability of severe aGvHD increased to 0.46 and of extensive cGvHD
to 0.6. If only one antigen 1 one allele or two alleles were mis-
matched, the probability of survival was as high as 0.65 and probabil-
ity of severe aGvHD as low as 0.19. In conclusion, the results of
MUD-PBSCT in a large prospective cohort of pts are similar if
not better than the results of MUD-BMT. There seems to be no in-
creased risk of severe GvHD after MUD-PBSCT. MUD-PBSCT
might offer a better disease control in patients with malignancies, es-
pecially with AML. With regard to the degree of HLA match it
seems that transplants from 8 of 10 allele matched donors (with max-
imum 1 mismatched antigen) influence neither survival nor inci-
dence of severe GvHD, whereas one should avoid performing
transplants from two antigen mismatched donors.130
REDUCED-INTENSITY CORD BLOOD TRANSPLANTATION FOR ADULT
PATIENTS WITH ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC
SYNDROME
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Objectives: To investigate relevant factors affecting the outcome
of reduced-intensity cord blood transplantation (RI-CBT), we ana-
lyzed retrospectively the results of 128 adult patients with acute
myeloid leukemia (AML)/ myelodysplastic syndrome (MDS) in Tor-
anomon hospital.
Patients and Methods: We reviewed medical records of 128
patients with AML/MDS who had received RI-CBT between
Feburuary 2002 and July 2007 at Toranomon Hospital, Tokyo,
Japan. The following factors were considered as potential predictors
of outcomes: patient’s age, ECOG performance status (PS), HLA
disparity, infused Total nucleated cell (TNC) dose/CD34 dose, dis-
ease/disease status, cytogenetics (SWOG/ECOG criteria) at UCBT,
acute graft versus host disease (GvHD) and chronic GvHD. All fac-
tors were tested for the proportional hazards assumption. Time to
event curves were plotted by using the actuarial method of Kaplan-
Meier and differences between curves were analyzed by log-rank
tests.
Results: Patient’s median age was 58 years (17–82). Diagnoses in-
clude de novo AML (n5 68), MDS overt AML (n5 35), refractory
anemia (RA) (n 5 10), and refractory anemia with excess of blasts
(RAEB) (n 5 14). Eighty patients, who were at PS 0 or 1, and 47
patients were PS 2 or more. Disease status consisted of standard
(n 5 17) and advanced (n 5 110). HLA disparities were 4/6 match
(n 5 83), 5/6 (n 5 39), and 6/6 (n 5 5). TNC/CD34 cell dose
were 2.510E7/kg (1.8–4.5) and 0.710E5/kg (0.1 – 2.0), respec-
tively. Main conditioning regimen was Fludarabine (125mg/m2)
1Melphalan (80mg/m2) 1TBI 4Gy. GvHD prophylaxis consisted
of tacrolimus (Tac) alone in 68, Tac plus mycophenolate mofetil
in 24, and cyclosporine alone in 35. All patient received single cord
blood unit. Neutrophil engraftment was achieved in 86% (median
21 days). Incidence of grade II-IV acute GvHD and chronic
GvHD were 40 and 22%, respectively. Transplantation -related
mortality (TRM) at 2-years was 48% (95% CI 37–58). Estimated
3-years Leukemia free survival (LFS) was 25% (95% CI 16–36)
and (standard risk 64% (95% CI 48–87) and high risk 17% (95%
CI 6–27)). In univariate analysis, variables associated with improved
survival were standard risk (P5 0.02) and PS 0–1 (p\0.001), while
other factors were not significant.
Discussion/Conclusion: We conclude that RI-CBT is a viable
therapeutic option for adult AML/MDS patients. Higher TRM
was the biggest problem to be solved to increase the feasibility of
this approach.
